Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy

Molecular Neurodegeneration

Volumn 11, Issue 1, 2016, Pages

  Congdon, Erin E ^a   Lin, Yan ^a   Rajamohamedsait, Hameetha B ^a   Shamir, Dov B ^a   Krishnaswamy, Senthilkumar ^a   Rajamohamedsait, Wajitha J ^a   Rasool, Suhail ^a   Gonzalez, Veronica ^a   Levenga, Josien ^a,b   Gu, Jiaping ^a   Hoeffer, Charles ^a,b   Sigurdsson, Einar M ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Alzheimer's disease; Antibodies; Immunotherapy; Paired helical filaments; Tau protein

Indexed keywords

EPITOPE; NEURON SPECIFIC NUCLEAR PROTEIN; PROTEIN ANTIBODY; TAU 4E6 ANTIBODY; TAU 6B2 ANTIBODY; TAU PROTEIN; UNCLASSIFIED DRUG; ANTIBODY;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CELL POPULATION; COGNITION; CONTROLLED STUDY; EX VIVO STUDY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; IN VIVO STUDY; INCUBATION TIME; MOUSE; NONHUMAN; PAIRED HELICAL FILAMENT; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SOLUBILIZATION; TAUOPATHY; WESTERN BLOTTING; ANIMAL; HUMAN; IMMUNOLOGY; METABOLISM; NERVE CELL; NEUROFIBRILLARY TANGLE; PATHOLOGY; PHOSPHORYLATION;

ALZHEIMER DISEASE; ANIMALS; ANTIBODIES; HUMANS; MICE; NEUROFIBRILLARY TANGLES; NEURONS; PHOSPHORYLATION; TAU PROTEINS; TAUOPATHIES;

EID: 84984831737     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/s13024-016-0126-z     Document Type: Article

References (46)

1. Asuni AA, et al. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci. 2007;27(34):9115-29.
2. Sigurdsson EM. Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. J Alzheimers Dis. 2008;15(2):157-68.
3. Sigurdsson EM, Wisniewski T, Frangione B. Infectivity of amyloid diseases. Trends Mol Med. 2002;8(9):411-3.
4. Congdon EE, Krishnaswamy S, Sigurdsson EM. Harnessing the immune system for treatment and detection of tau pathology. J Alzheimers Dis. 2014;40 Suppl 1:S113-21.
5. Pedersen JT, Sigurdsson EM. Tau immunotherapy for Alzheimer's disease. Trends Mol Med. 2015;21(6):394-402.
6. Goedert M, et al. Prion-like mechanisms in the pathogenesis of tauopathies and synucleinopathies. Curr Neurol Neurosci Rep. 2014;14(11):495.
7. Walker LC, et al. Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol. 2013;70(3):304-10.
8. Nelson PT, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71(5):362-81.
9. Collin L, et al. Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease. Brain. 2014;137(Pt 10):2834-46.
10. Congdon EE, et al. Antibody uptake into neurons occurs primarily via clathrin-dependent Fcgamma receptor endocytosis and is a prerequisite for acute tau protein clearance. J Biol Chem. 2013;288(49):35452-65.
11. Gu J, Congdon EE, Sigurdsson EM. Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology. J Biol Chem. 2013;288(46):33081-95.
12. Kondo A, et al. Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature. 2015;523(7561):431-6.
13. Krishnamurthy PK, Deng Y, Sigurdsson EM. Mechanistic studies of antibody-mediated clearance of Tau aggregates using an ex vivo brain slice model. Front Psychiatry. 2011;2:59.
14. Krishnaswamy S, et al. Antibody-derived in vivo imaging of tau pathology. J Neurosci. 2014;34(50):16835-50.
15. Castillo-Carranza DL, et al. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci. 2014;34(12):4260-72.
16. d'Abramo C, et al. Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. PLoS One. 2013;8(4), e62402.
17. Yanamandra K, et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80(2):402-14.
18. Bumbaca D, et al. Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. AAPS J. 2012;14(3):554-8.
19. Igawa T, et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel. 2010;23(5):385-92.
20. Andorfer C, et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem. 2003;86(3):582-90.
21. Davis J, et al. Lost in transgenesis: a user's guide for genetically manipulating the mouse in cardiac research. Circ Res. 2012;111(6):761-77.
22. Henriques A, Pitzer C, Schneider A. Characterization of a novel SOD-1(G93A) transgenic mouse line with very decelerated disease development. PLoS One. 2010;5(11), e15445.
23. Lee VM, Wang J, Trojanowski JQ. Purification of paired helical filament tau and normal tau from human brain tissue. Methods Enzymol. 1999;309:81-9.
24. Levenga J, et al. Tau pathology induces loss of GABAergic interneurons leading to altered synaptic plasticity and behavioral impairments. Acta Neuropathol Commun. 2013;1:34.
25. Fa M, Puzzo D, Piacentini R, Staniszewski A, Zhang H, Baltrons MA, et al. Extracellular tau oligomers produce an immediate impairment of LTP and memory. Sci Rep. 2016;6:19393.
26. Funk KE, et al. Distinct therapeutic mechanisms of Tau antibodies: promoting microglial clearence versus blocking neuronal uptake. J Biol Chem. 2015;290(35):21652-62.
27. Luo W, et al. Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody. Sci Rep. 2015;5:11161.
28. Masliah E, et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One. 2011;6(4), e19338.
29. Lewis J, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000;25(4):402-5.
30. Boutajangout A, et al. Cognitive and sensorimotor tasks for assessing functional impairments in mouse models of Alzheimer's disease and related disorders. Methods Mol Biol. 2012;849:529-40.
31. Chang E, et al. Pathogenic missense MAPT mutations differentially modulate tau aggregation propensity at nucleation and extension steps. J Neurochem. 2008;107(4):1113-23.
32. Congdon EE, et al. Nucleation-dependent tau filament formation: the importance of dimerization and an estimation of elementary rate constants. J Biol Chem. 2008;283(20):13806-16.
33. Shammas SL, et al. A mechanistic model of tau amyloid aggregation based on direct observation of oligomers. Nat Commun. 2015;6:7025.
34. Congdon EE, et al. Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy. 2012;8(4):609-22.
35. Pecho-Vrieseling E, et al. Transneuronal propagation of mutant huntingtin contributes to non-cell autonomous pathology in neurons. Nat Neurosci. 2014;17(8):1064-72.
36. Rajamohamedsait HB, Sigurdsson EM. Histological staining of amyloid and pre-amyloid peptides and proteins in mouse tissue. Methods Mol Biol. 2012;849:411-24.
37. Lasagna-Reeves CA, et al. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep. 2012;2:700.
38. Murphy KE, et al. Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson's disease. Brain. 2014;137(Pt 3):834-48.
39. Park S, Jung Y. Combined actions of Na/K-ATPase, NCX1 and glutamate dependent NMDA receptors in ischemic rat brain penumbra. Anat Cell Biol. 2010;43(3):201-10.
40. McKiernan RC, et al. Reduced mature microRNA levels in association with dicer loss in human temporal lobe epilepsy with hippocampal sclerosis. PLoS One. 2012;7(5), e35921.
41. Karuppagounder SS, et al. Changes in inflammatory processes associated with selective vulnerability following mild impairment of oxidative metabolism. Neurobiol Dis. 2007;26(2):353-62.
42. Lesuisse C, Martin LJ. Long-term culture of mouse cortical neurons as a model for neuronal development, aging, and death. J Neurobiol. 2002;51(1):9-23.
43. Ryu HW, Park CW, Ryu KY. Disruption of polyubiquitin gene Ubb causes dysregulation of neural stem cell differentiation with premature gliogenesis. Sci Rep. 2014;4:7026.
44. Jin N, et al. Truncation and activation of GSK-3beta by calpain I: a molecular mechanism links to tau hyperphosphorylation in Alzheimer's disease. Sci Rep. 2015;5:8187.
45. Asuni AA, et al. Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages. Eur J Neurosci. 2006;24(9):2530-42.
46. Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci. 2010;30(49):16559-66.